Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis

PAC203 is a randomized dose-finding study of pacritinib, an oral JAK2/IRAK1 inhibitor, in patients with advanced myelofibrosis who are intolerant of or resistant to ruxolitinib. Patients were randomized 1:1:1 to pacritinib 100 mg once per day, 100 mg twice per day, or 200 mg twice per day. Enhanced...

Full description

Bibliographic Details
Main Authors:	Gerds, AT, Savona, MR, Scott, BL, Talpaz, M, Egyed, M, Harrison, CN, Yacoub, A, Vannucchi, A, Mead, AJ, Kiladjian, J-J, O'Sullivan, J, García-Gutiérrez, V, Bose, P, Rampal, RK, Miller, CB, Palmer, J, Oh, ST, Buckley, SA, Mould, DR, Ito, K, Tyavanagimatt, S, Smith, JA, Roman-Torres, K, Devineni, S, Craig, AR, Mascarenhas, JO
Format:	Journal article
Language:	English
Published:	American Society of Hematology 2020

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis

Similar Items